LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New AI Tool Classifies Brain Tumors More Quickly and Accurately

By LabMedica International staff writers
Posted on 20 May 2024
Print article
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based profiling. DNA methylation functions as a regulatory mechanism to control gene activity, essentially turning genes on or off. However, the time required for such testing can be a significant hindrance, often taking several weeks—a delay that can be critical when patients need prompt decisions regarding their treatment. Additionally, these tests are not widely available in most hospitals around the world. Now, a new artificial intelligence (AI) tool has been developed to classify brain tumors more quickly and accurately.

Researchers at The Australian National University (ANU, Canberra, Australia) have created DEPLOY. This new method predicts DNA methylation patterns to classify brain tumors into 10 major subtypes. DEPLOY utilizes histopathology images, which are microscopic images of patient tissue samples. The model was trained and validated on extensive datasets comprising around 4,000 patients from the US and Europe. DEPLOY demonstrated remarkable accuracy, achieving a rate of 95%. Additionally, in a subset of 309 samples that were particularly challenging to classify, DEPLOY provided diagnoses that were more clinically relevant than those initially given by pathologists. The researchers anticipate that DEPLOY could also be adapted for classifying other types of cancer in the future.

“This shows the potential future role of DEPLOY as a complementary tool, adding to a pathologist’s initial diagnosis, or even prompting re-evaluation in the case of disparities,” said Dr. Danh-Tai Hoang.

Related Links:
ANU

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.